[Azidothymidine in the treatment of patients with human immunodeficiency virus infection and persistent generalized adenopathies].
The effectiveness and security of azidothymidine (AZT) in the treatment of patients with infection by the human immunodeficiency virus (HIV) and persistent generalized adenopathies (PGA), were assessed. Thirty six patients with HIV infection and PGA participate in the study. Eighteen were treated with AZT and the other 18 were included in the control group, since they did not accept the treatment. Both groups were homogeneous with respect to their clinical, immunological and virological characteristics. A common study protocol was used and the clinical, immunological and virological effectiveness was assessed. Lymphocyte subpopulations were quantified by flow cytometry, viral antigens were determined by sandwich-type ELISA and antibodies against viral proteins (anti-gp120, anti-gp160, anti-gp41, anti-gp24 and anti-p18) were detected by Western blot. Naranjo and Busto's algorithm was used for the causality of adverse effects. We did not observe any significant differences regarding the presence of infection and the evolution of AIDS in both groups. A positive response to thrombocytopenia was observed, more evident in patients under low doses of AZT. The small initial transitory improvement of the immunological parameters was not statistically significant. The viral antigen was not modified by the treatment. With respect to the behaviour of the several antibodies studied, no differences were observed. The initial doses of AZT had to be modified in 44% of patients due to their hematological toxicity, more frequent in the first stages of the treatment. In two patients, the treatment had to be finally discontinued due to severe neutropenia. 25% of patients showed mild to moderate gastrointestinal manifestations.(ABSTRACT TRUNCATED AT 250 WORDS)
Valencia
E
E
Servicio de Medicina Interna, Hospital La Paz, Universidad Autónoma, Madrid.
Gil
A
A
Zapico
R M
RM
García Rodríguez
M C
MC
Pintado
V
V
López Dupla
M
M
Lavilla
P
P
Camacho
J
J
D000386:AIDS-Related Complex / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D016009:Chi-Square Distribution; D004305:Dose-Response Relationship, Drug; D015658:HIV Infections / Q000188:drug therapy* / Q000453:epidemiology / Q000276:immunology; D015497:HIV-1; D006801:Humans; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000276:immunology; D011446:Prospective Studies; D013997:Time Factors; D015215:Zidovudine / Q000009:adverse effects / Q000627:therapeutic use*
D015215:Zidovudine
La azidotimidina en el tratamiento de los pacientes con infección por el virus de la inmunodeficiencia humana y adenopatías generalizadas persistentes.